Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2012
12/20/2012US20120321664 Modulation of yeast-based immunotherapy products and responses
12/20/2012US20120321663 Live vaccine for avian diseases
12/20/2012US20120321662 Methods of Eliciting or Boosting a Cellular Immune Response
12/20/2012US20120321661 Recombinant Measles Virus Useful as a Bivalent Vaccine Against Measles and Malarial Infections
12/20/2012US20120321660 Conjugation process of bacterial polysaccharides to carrier proteins
12/20/2012US20120321659 Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
12/20/2012US20120321658 Immunogenic composition comprising s. pneumoniae polysaccharides conjugated to carrier proteins
12/20/2012US20120321657 Group a streptococcus multivalent vaccine
12/20/2012US20120321656 Oligopeptides and their use for treating infectious diseases
12/20/2012US20120321655 Lentivirus vaccine based on the recombinant viral vaccine against yellow fever
12/20/2012US20120321654 Infectious clones of torque teno virus
12/20/2012US20120321653 Novel chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof
12/20/2012US20120321652 Peptides for active anti-cytokine immunization
12/20/2012US20120321651 Anti-IGE Vaccines
12/20/2012US20120321650 Composition for the treatment of atherosclerosis
12/20/2012US20120321649 Peptide Vaccines for Cancers Expressing Tumor-Associated Antigens
12/20/2012US20120321648 Use of islet glucose-6-phosphatase related protein as a diagnostic tool and therapeutic target for autoimmune diabetes
12/20/2012US20120321647 Structured rna motifs and compounds and methods for their use
12/20/2012US20120321646 Methods for Enhancing Anti-Tumor Antibody Therapy
12/20/2012US20120321645 Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
12/20/2012US20120321644 Methods for diagnosing mood disorders
12/20/2012US20120321643 Anti-epidermal growth factor receptor antibodies and uses thereof
12/20/2012US20120321642 Methods of Treating Gout using IL-1beta Antagonists
12/20/2012US20120321641 Pharmaceutical composition for treating and/or preventing cancer
12/20/2012US20120321640 Von willebrand factor specific binding agents and uses thereof
12/20/2012US20120321639 Methods and compositions for the inhibition of stat5 in prostate cancer cells
12/20/2012US20120321638 Formulation comprising an antibody against p-selectin
12/20/2012US20120321637 Combination cancer therapy with herv inhibition
12/20/2012US20120321636 Antibodies specific for sclerostin and methods for increasing bone mineralization
12/20/2012US20120321635 Composition Containing Inhibitors of the Expression or Activity of SH3RF2 for Preventing or Treating Cancer
12/20/2012US20120321634 Estrogen receptors and methods of use
12/20/2012US20120321633 Anti-human epo receptor antibodies and methods of use
12/20/2012US20120321632 Neutralizing prolactin receptor antibodies and their therapeutic use
12/20/2012US20120321631 Anti-inflammatory agents
12/20/2012US20120321630 Antibodies against g-csfr and uses thereof
12/20/2012US20120321629 Stem cell factor inhibitor
12/20/2012US20120321628 Hepatocyte growth factor receptor antagonists and uses thereof
12/20/2012US20120321627 Bispecific anti-vegf/anti-ang-2 antibodies
12/20/2012US20120321626 Multi-specific fab fusion proteins and methods of use
12/20/2012US20120321625 Antibodies to ox-2/cd200 and uses thereof in inhibiting immune responses
12/20/2012US20120321624 Targeting the neuromuscular junction for treatment
12/20/2012US20120321623 ILT3 Polypeptides and Uses Thereof
12/20/2012US20120321622 Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases
12/20/2012US20120321621 INHIBITION OF FcyR-MEDIATED PHAGOCYTOSIS WITH REDUCED IMMUNOGLOBULIN PREPARATIONS
12/20/2012US20120321620 Methods and compositions for inhibiting cd32b expressing cells
12/20/2012US20120321619 Anti-c4.4a antibodies and uses thereof
12/20/2012US20120321618 Humanized anti-il 10 antibodies for the treatment of systemic lupus erythematosus (sle)
12/20/2012US20120321617 Humanized anti-il 10 antibodies for the treatment of systemic lupus erythematosus (sle)
12/20/2012US20120321616 Stabilized liquid anti-rsv antibody formulations
12/20/2012US20120321615 Assay for Metastatic Colorectal Cancer
12/20/2012US20120321614 Antibodies to c-met
12/20/2012US20120321613 Molecular targets for healing or treating wounds
12/20/2012US20120321598 Vectors and methods for long-term immune evasion to prolong tranplant viability
12/20/2012US20120321594 Methods of controlling axon or dendrite development of neuronal cells
12/20/2012US20120321591 Anti-angiogenic compounds
12/20/2012US20120321589 Antibody Fusion Proteins with Disrupted Heparin-Binding Activity
12/20/2012US20120321575 Use of kif13a and ap-1 inhibitors for inhibiting melanogenesis
12/20/2012US20120321556 Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma
12/20/2012US20120321554 Plexin d1 as a target for tumor diagnosis and therapy
12/20/2012US20120321553 Ultrafiltration Concentration of Allotype Selected Antibodies for Small-Volume Administration
12/20/2012US20120321552 Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin
12/20/2012US20120318262 Pyrvinium Wound Treatment Methods and Devices
12/20/2012CA2841416A1 Method of selecting therapeutic indications
12/20/2012CA2839755A1 Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
12/20/2012CA2839009A1 Rabies virus like particle production in plants
12/20/2012CA2838981A1 Group a streptococcus multivalent vaccine
12/20/2012CA2838952A1 Anti-psgl-1 antibodies and uses thereof
12/20/2012CA2838950A1 Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
12/20/2012CA2838888A1 A method for the production of hydrolyzed allergens
12/20/2012CA2838867A1 Anti-angptl3 antibodies and uses thereof
12/20/2012CA2838246A1 Antibodies against g-csfr and uses thereof
12/20/2012CA2838220A1 Selective elimination of erosive cells
12/20/2012CA2837892A1 Tem8 antibodies, conjugates thereof, and their use
12/19/2012EP2535409A1 Method for producing recombinant virus
12/19/2012EP2535405A1 A recombinant a/astanarg/6:2/2009 m-12-09/d flu virus strain produced by a reverse genetics method from a highly pathogenic donor strain a/chicken/astana/6/05 (h5n1) and a highly reproductive donor strain a/puerto rico/8/34 (h1n1) from the orthomyxoviridae family of the genus influenza virus type a which is deposited in the microorganism collection of the science committee at the ministry of education and science of the republic of kazakhstan state enterprise subsidiary of the scientific research institute for biological safety problems at the republican state enterprise of the national centre for biotechnology of the republic of kazakhstan and can be used in biotechnology for the production of diagnostic and vaccine preparations against a/h5n1 flu
12/19/2012EP2535358A1 Radioactive metal-labeled anti-cadherin antibody
12/19/2012EP2535355A2 Antibodies against CD38 for treatment of multiple myeloma
12/19/2012EP2535354A1 Antibodies to human programmed death receptor PD-1
12/19/2012EP2535353A1 Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
12/19/2012EP2535352A1 Pharmaceutical compound with antibodies against catalase and superoxide dismutase for tumour treatment
12/19/2012EP2535058A2 Stabilization of vaccines by lyophilization
12/19/2012EP2534179A2 Upar binding agents and methods of use thereof
12/19/2012EP2534178A1 Therapeutic methods using an ti-cd200 antibodies
12/19/2012EP2534176A1 Agonist dr5 binding polypeptides
12/19/2012EP2533811A2 Multimeric proteins comprising immunoglobulin constant domains
12/19/2012EP2533810A1 Cd20 antibodies and uses thereof
12/19/2012EP2533809A1 Lipidated antigens and use thereof for enhancing an immunological response
12/19/2012EP2533808A1 Process for producing an allergen extract
12/19/2012EP2533807A2 Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
12/19/2012EP2533806A2 Methods and materials for treating cancer
12/19/2012EP2533805A1 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
12/19/2012EP2533804A1 Antibody drug conjugates (adc) that bind to 161p2f10b proteins
12/19/2012EP2533798A2 P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
12/19/2012EP2533779A2 Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase
12/19/2012CN102834512A Metal salen complex derivative and process for production thereof
12/19/2012CN102834414A Antibodies against csf-1r
12/19/2012CN102834413A Treatment of a metabolic disorder
12/19/2012CN102834412A Integrin avss8 neutralizing antibody
12/19/2012CN102834410A Factor h binding proteins (fhbp) with altered properties and methods of use thereof
12/19/2012CN102834118A Composition comprising the amyloid beta 1-6 peptide coupled to virus-like particle and an adjuvant
1 ... 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 ... 1823